DERMATOLOGIC ADVERSE EVENTS WITHIN THE FIRST 60 DAYS OF SORAFENIB TREATMENT ARE ASSOCIATED WITH BETTER OVERALL SURVIVAL (OS) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

被引：0
|
作者：
Reig, M. [1 ]
Rodriguez de Lope, C. [1 ]
Llarch, N. [1 ]
Forner, A. [1 ]
Torres, F. [2 ]
Rios, J. [2 ]
Boix, L. [1 ]
Rimola, J. [3 ]
Darnell, A. [3 ]
Ayuso, C. [3 ]
Bruix, J. [1 ]
机构：
[1] Univ Barcelona, BCLC Grp, Liver Unit, CIBERehd,IDIBAPS,Hosp Clin, Barcelona, Spain
[2] Univ Autonoma Barcelona, IDIBAPS, Hosp Clin Barcelona, Unidad Bioestadist,Fac Med, E-08193 Barcelona, Spain
[3] Univ Barcelona, BCLC Grp, Dept Radiol, CIBERehd,IDIBAPS,Hosp Clin, Barcelona, Spain
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60269-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
267
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [31] ALBI score affects Overall Survival (OS) in patients with hepatocellular carcinoma (HCC) treated with selective internal radiation therapy (SIRT)
    Cioffi, M.
    Grimaldi, S.
    Fronda, M.
    Breatta, A. Doriguzzi
    Rovera, G.
    Passera, R.
    Fonio, P.
    Morbelli, S.
    Finessi, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S411 - S411
  • [32] Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
    Kudo, Masatoshi
    Finn, Richard S.
    Meyer, Tim
    Boisserie, Frederic
    Li, Songzi
    Chen, Yaxi
    Abdrashitov, Ramil
    Zhu, Andrew X.
    Vogel, Arndt
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] IMPACT OF HEPATITIS C VIRUS (HCV) TREATMENT, TYPE OF HEPATOCELLULAR CARCINOMA (HCC) TREATMENT, AND ETHNICITY ON OVERALL SURVIVAL IN PATIENTS WITH HCV-RELATED HCC
    Nguyen, Veronica
    Arteaga, Christopher
    Anderson, Colin
    Cui, Haiyan
    Roe, Denise
    Shroff, Rachna T.
    HEPATOLOGY, 2021, 74 : 647A - 647A
  • [34] Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis
    Raoul, Jean-Luc
    Adhoute, Xavier
    Penaranda, Guillaume
    Perrier, Herve
    Castellani, Paul
    Oules, Valerie
    Bourliere, Marc
    LIVER CANCER, 2019, 8 (06) : 457 - 467
  • [35] Effect of sorafenib combined with CIK cell treatment on immunity and adverse events in patients with late-stage hepatocellular carcinoma
    Liu, Zhao-Zhe
    Gu, Jia
    Han, Tao
    Guo, Fang
    Li, Qiu-Hua
    Sun, Qing-Qing
    Guo, Xing
    Zheng, Zhen-Dong
    Xie, Xiao-Dong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 4625 - 4629
  • [36] Healthcare Delivery System is Associated with Curative Treatment Receipt and Overall Survival in Patients with Hepatocellular Carcinoma
    Rich, Nicole E.
    Yopp, Adam C.
    Marrero, Jorge A.
    Kalva, Sanjeeva
    Odewole, Mobolaji
    Canales, Angelica
    Singal, Amit G.
    HEPATOLOGY, 2017, 66 : 727A - 728A
  • [37] The correlation between adverse events and survival benefits of donafenib in the first-line treatment of advanced hepatocellular carcinoma
    Bi, F.
    Qin, S.
    Xu, J.
    Du, C.
    Fan, Q.
    Zhang, L.
    Tao, M.
    Jiang, D.
    Wang, S.
    Chen, Y.
    Sheng, J.
    Zhuang, X.
    Wu, J.
    Liu, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S128 - S128
  • [38] IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).
    Ducreux, Michel
    Zhu, Andrew X.
    Cheng, Ann-Lii
    Galle, Peter R.
    Ikeda, Masafumi
    Nicholas, Alan
    Verret, Wendy
    Li, Lindong
    Gaillard, Vincent E.
    Lencioni, Riccardo
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis
    Rizzo, Alessandro
    Carloni, Riccardo
    Ricci, Angela Dalia
    Cusmai, Antonio
    Laforgia, Mariarita
    Calabro, Concetta
    Ungaro, Valentina
    Oreste, Donato
    Sollitto, Mario
    Palmiotti, Gennaro
    Brandi, Giovanni
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (04) : 323 - 329
  • [40] The volume of enhancement of disease (VED) predicts the early response to treatment and overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib
    Campani, C.
    Colagrande, S.
    Calistri, L.
    Dragoni, G.
    Lorini, C.
    Castellani, A.
    Marra, F.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : E51 - E52
12345